Abstract:Over the past two decades, immunotherapies have increasingly been considered as first-line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB), which has demonstrated promising results against various solid tumors in clinical trials. Monoclonal antibodies (mAbs) are currently available as immune checkpoint inhibitors (ICIs). These ICIs target specific immune checkpoints, including cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1). Clinical trial results strongly support the feasibility of this immunotherapeutic approach. However, a substantial proportion of patients with cancer develop resistance or tolerance to treatment, owing to tumor immune evasion mechanisms that counteract the host immune response. Consequently, substantial research focus has been aimed at identifying additional ICIs or synergistic inhibitory receptors to enhance the effectiveness of anti-PD-1, anti-programmed cell death ligand 1 (anti-PD-L1), and anti-CTLA-4 treatments. Recently, several immune checkpoint molecular targets have been identified, such as T cell immunoreceptor with Ig and ITIM domains (TIGIT), mucin domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), V-domain immunoglobulin suppressor of T cell activation (VISTA), B and T lymphocyte attenuator (BTLA), and signal-regulatory protein α (SIRPα). Functional mAbs targeting these molecules are under development. CTLA-4, PD-1/PD-L1, and other recently discovered immune checkpoint proteins with distinct structures are at the forefront of research. This review discusses these structures, as well as clinical progress in mAbs targeting these immune checkpoint molecules and their potential applications.

Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Bispecific Antibodies Targeting Immunomodulator Y Checkpoints for Cancer Therapy

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

The present and future of bispecific antibodies for cancer therapy

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Bispecific antibodies: advancing precision oncology

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Bispecific Antibodies in the Treatment of Hematologic Malignancies

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

The landscape of bispecific T cell engager in cancer treatment